New Gadolinium Chelate Compounds for Use in Magnetic Resonance Imaging
Bayer Pharma Aktiengesellschaft
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application PCT/EP2016/062105, filed May 30, 2016. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,137,209 | New Gadolinium Chelate Compounds for Use in Magnetic Resonance Imaging In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | ||
| US 10,722,601 | Gadolinium Chelate Compounds for Use in Magnetic Resonance Imaging In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | ||
| US 11,491,245 | Gadolinium Chelate Compounds for Use in Magnetic Resonance Imaging In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | ||
| US 12,478,696 | Gadolinium Chelate Compounds for Use in Magnetic Resonance Imaging In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | ||
| Application 17/979,367 | New Gadolinium Chelate Compounds for Use in Magnetic Resonance Imaging Pending Not granted | Bayer Pharma Aktiengesellschaft | Pending | Not granted |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Bayer Pharma Aktiengesellschaft.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.